Press Releases

Investors

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Research Corporation Completes $5.5 Million Private Placement
At Market Offering Led by Noted Investor, Jim Mellon; Proceeds to Fund Nanomedicine Programs
View HTML
Toggle Summary Arrowhead Reports Fiscal 2011 Third Quarter Financial Results
Calando Completes Phase 1 Trial; Initiates Phase 1b
View HTML
Toggle Summary Arrowhead Research to Report Fiscal 2011 Third Quarter Financial Results and Host Conference Call on Monday, August 8, 2011
Arrowhead Research to Report Fiscal 2011 Third Quarter Financial Results and Host Conference Call on Monday, August 8, 2011 PASADENA, Calif. — August 1, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it will report its financial results for the fiscal 2011 third quarter
View HTML
Toggle Summary Arrowhead Research Announces Oncology Expert Timothy J. Triche to Join Calando Scientific Advisory Board
Arrowhead Research Announces Oncology Expert Timothy J. Triche to Join Calando Scientific Advisory Board PASADENA, Calif. — July 26, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity and regenerative medicine, today announced
View HTML
Toggle Summary Arrowhead Research to Present at Two Nanomedicine-Focused Events in London
Arrowhead Research to Present at Two Nanomedicine-Focused Events in London PASADENA, Calif. – June 21, 2011 – Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that its President and Chief
View HTML
Toggle Summary Arrowhead Research President & CEO Christopher Anzalone Featured in The Wall Street Transcript Interview
Arrowhead Research President & CEO Christopher Anzalone Featured in The Wall Street Transcript Interview PASADENA, Calif. – June 16, 2011 – Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today
View HTML
Toggle Summary Arrowhead Receives Additional 180 Day Grace Period to Comply with the NASDAQ $1.00 Minimum Bid Requirement
Arrowhead Receives Additional 180 Day Grace Period to Comply with the NASDAQ $1.00 Minimum Bid Requirement PASADENA, Calif. – June 9, 2011 – Arrowhead Research Corporation (NASDAQ: ARWR) today announced that, on June 7, 2011, it received a notification from the NASDAQ Stock Market indicating that
View HTML
Toggle Summary Arrowhead Reports Fiscal 2011 Second Quarter Financial Results
Arrowhead Reports Fiscal 2011 Second Quarter Financial Results PASADENA, Calif. – May 12, 2011 – Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced financial results for its fiscal 2011
View HTML
Toggle Summary Arrowhead Research to Report Fiscal 2011 Second Quarter Financial Results and Host Conference Call on Thursday, May 12, 2011
Arrowhead Research to Report Fiscal 2011 Second Quarter Financial Results and Host Conference Call on Thursday, May 12, 2011 PASADENA, Calif. — May 4, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR) , a nanomedicine company with development programs in oncology, obesity and regenerative
View HTML
Toggle Summary Arrowhead Research to Present at the 2011 MDB Capital Group Bright Lights Conference on May 10
Arrowhead Research to Present at the 2011 MDB Capital Group Bright Lights Conference on May 10 PASADENA, Calif. — May 3, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR) , a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that Dr.
View HTML